Treatment for alopecia areata depends on the diagnosis, extent of hair loss, age, health and personal priorities. Some people regrow hair without treatment; others have persistent or recurrent loss. Neither possibility is a reason to promise a cure or dismiss the emotional burden. 1 2
Alopecia areata is not the same condition as inherited pattern hair loss. Establishing the type matters before applying evidence from a hair-growth product or a drug trial to the person in front of the clinician. 3
Local and systemic treatments answer different needs
For selected limited patches, clinicians may consider local corticosteroid treatment. More extensive disease can lead to discussion of systemic medicines, including JAK inhibitors with defined age and severity indications. Suitability and monitoring differ between products. Not every option discussed in specialist practice is licensed for every situation. 2
There is also a choice not to pursue a medical treatment. Wigs, head coverings, eyebrow cosmetics and psychological support can address important practical needs without making an unsupported biological claim. 2
What did the Leqselvi approval evidence show?
The FDA's original approval snapshot identifies Leqselvi, or deuruxolitinib, for adults with severe alopecia areata. Its original US approval date was July 25, 2024. The snapshot describes two randomized placebo-controlled trials, not a comparison against all other alopecia treatments. 4
At 24 weeks, approximately 29% and 32% of participants receiving the studied regimen in the two trials reached at least 80% scalp hair coverage, compared with about 1% in each placebo group. This endpoint does not mean every participant regrew 29% or 32% of their hair, and it does not mean everyone achieved complete regrowth. 4
The FDA record also describes serious risks, including infections and other major adverse effects associated with the treatment. The potential benefit needs assessment alongside contraindications, other medicines and the required monitoring. These trial figures are historical approval evidence, not a guarantee of present availability, insurance payment or an individual's response. 4
How to read a “hair regrowth” percentage
Imagine a hypothetical study in which 30 out of 100 people reach a specified coverage threshold. That could be described as a 30% response rate. It would not establish that the average person gained 30% coverage. Nor would it show how the other 70 participants fared without additional outcome data.
When comparing reports, ask whether the number represents people meeting a threshold, change from baseline, eyebrow or eyelash outcomes, or a quality-of-life measure. Also check the assessment time. These are different questions, not interchangeable ways to announce the same success.
What needs to be agreed before starting?
Ask the prescriber what the treatment is intended to accomplish, when the response will be assessed, what monitoring is needed and what would justify continuing, changing or stopping it. Request a plan for adverse effects and a discussion of uncertainty after discontinuation rather than assuming a course permanently resets the condition.
The cost discussion should include medication, appointments, tests and the duration actually proposed. No reliable personal cost can be obtained by multiplying a list price by an assumed treatment length. This article does not establish a comparative price or preferred drug.
Keep the underlying diagnosis visible
Hair loss from tension, infection, medication or a different scalp disease needs its own assessment. An alopecia areata trial does not establish effectiveness for other causes. 3
Use the alopecia types guide to understand the terminology, then discuss the actual diagnosis and goals with a qualified clinician. This is treatment evidence explained, not a prescription or a ranked shopping list.
A response-rate example, unpacked
| Statement about the historical Leqselvi trials | What it means |
|---|---|
| Roughly 29% and 32% reached the reported threshold at week 24 | The proportion of people meeting a defined scalp-coverage outcome in each trial |
| At least 80% scalp hair coverage | The endpoint reached, not an 80% response rate |
| About 1% in each placebo group reached it | The contemporaneous trial comparison—not a comparison with every other drug |
The FDA snapshot describes the original approval evidence. It does not establish which current treatment is best for an individual or what their insurer will cover. 4
Can separate trial percentages rank all JAK medicines?
Not responsibly without examining whether populations, endpoints, timing and study methods match. The site's research-comparison worksheet keeps those fields visible; it does not choose a treatment.
What belongs in the cost discussion?
Write down the exact prescribed product, planned review interval, appointments, tests and any other quoted costs. Do not multiply a headline price by an invented lifelong treatment duration. The medical estimate guide keeps unknowns visible instead of disguising them as zero.